open access

Vol 13, No 6 (2008)
Untitled
Published online: 2008-11-01
Submitted: 2008-09-01
Get Citation

Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.

Jadwiga NOWAK-SADZIKOWSKA, Teresa KOWALSKA, Jerzy JAKUBOWICZ, Teresa SZPYTMA
DOI: 10.1016/S1507-1367(10)60016-8
·
Rep Pract Oncol Radiother 2008;13(6):300-308.

open access

Vol 13, No 6 (2008)
Untitled
Published online: 2008-11-01
Submitted: 2008-09-01

Abstract

Background

Curative treatment options for invasive bladder cancer include radical cystectomy and therapeutic strategies with bladder preservation.

Aim

To evaluate the toxicity and clinical effectiveness of transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin in muscle invasive bladder cancer.

Materials and Methods

Between October 2005 and March 2008, 27 patients with histologically proven invasive carcinoma of the bladder (T2-4a,N0-1,M0) who were fit for combined radiochemotherapy and refused radical surgery were selected to bladder-sparing protocol.

Results

In this study, a group of twenty one patients (78%) received two cycles of chemotherapy, and six of them (22%) only one, because of treatment related toxicity. Complete response after finished conservative treatment: transurethral resection, neoadjuvant chemotherapy with gemcytabin and cisplatin, and accelerated hyperfractionated radiotherapy with concomitant boost plus concurrent cisplatin, occurred in 18 patients (67%), partial response in 2 (8%), stable disease in 7(25%). Toxicities for hematologic and nonhematologic parameters during neoadjuvant chemotherapy were acceptable.

Conclusion

Conservative treatment in patients with muscle-invasive bladder cancer provides a high probability of local response with acceptable toxicity in properly selected patients.

Abstract

Background

Curative treatment options for invasive bladder cancer include radical cystectomy and therapeutic strategies with bladder preservation.

Aim

To evaluate the toxicity and clinical effectiveness of transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin in muscle invasive bladder cancer.

Materials and Methods

Between October 2005 and March 2008, 27 patients with histologically proven invasive carcinoma of the bladder (T2-4a,N0-1,M0) who were fit for combined radiochemotherapy and refused radical surgery were selected to bladder-sparing protocol.

Results

In this study, a group of twenty one patients (78%) received two cycles of chemotherapy, and six of them (22%) only one, because of treatment related toxicity. Complete response after finished conservative treatment: transurethral resection, neoadjuvant chemotherapy with gemcytabin and cisplatin, and accelerated hyperfractionated radiotherapy with concomitant boost plus concurrent cisplatin, occurred in 18 patients (67%), partial response in 2 (8%), stable disease in 7(25%). Toxicities for hematologic and nonhematologic parameters during neoadjuvant chemotherapy were acceptable.

Conclusion

Conservative treatment in patients with muscle-invasive bladder cancer provides a high probability of local response with acceptable toxicity in properly selected patients.

Get Citation

Keywords

radiotherapy; chemotherapy; bladder cancer; bladder preservation

About this article
Title

Conservative treatment in patients with muscle-invasive bladder cancer by transurethral resection, neoadjuvant chemotherapy with gemcitabine and cisplatin, and accelerated radiotherapy with concomitant boost plus concurrent cisplatin – assessment of response and toxicity.

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 13, No 6 (2008)

Pages

300-308

Published online

2008-11-01

DOI

10.1016/S1507-1367(10)60016-8

Bibliographic record

Rep Pract Oncol Radiother 2008;13(6):300-308.

Keywords

radiotherapy
chemotherapy
bladder cancer
bladder preservation

Authors

Jadwiga NOWAK-SADZIKOWSKA
Teresa KOWALSKA
Jerzy JAKUBOWICZ
Teresa SZPYTMA

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl